ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Features and development of Coot

Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

PHENIX : a comprehensive Python-based system for macromolecular structure solution

Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716

Phaser crystallographic software

McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612

SWISS-MODEL: homology modelling of protein structures and complexes

Waterhouse, A. M., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F. T., de Beer, T., Rempfer, C., Bordoli, L., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky427 · Cited by 13,248

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Adams, P. D., Afonine, P. V., Bunkòczi, G., Chen, V. B., Davis, I., Echols, N., Headd, J. J., Hung, L., Kapral, G. J., Grosse‐Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770

Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,497

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Long, G. V., Stroyakovskiy, D., Gogas, H. J., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60898-4 · Cited by 1,435

BRAF mutation predicts sensitivity to MEK inhibition

Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga‐Kalabis, M., Cipolla, A. K., Wubbenhorst, B. S., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,289

RAS-targeted therapies: is the undruggable drugged?

Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V. G., Liszkay, G., Giacomo, A. M. D., Mandalà, M., Демидов, Л. В., Stroyakovskiy, D., Thomas, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30122-x · Cited by 1,041

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A. M., Mandalà, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30142-6 · Cited by 1,034

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

Bueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., Rienzo, A. D., Modrusan, Z. D., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 937

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

Allen, E. M. V., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., Place, C. S., Taylor-Weiner, A. N., Whittaker, S. R., Kryukov, G. V., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0617 · Cited by 921

An Optimized microRNA Backbone for Effective Single-Copy RNAi

Fellmann, C., Hoffmann, T., Sridhar, V., Hopfgartner, B., Muhar, M., Roth, M., Lai, D. Y., Barbosa, I. A. M., Kwon, J. S., Guan, Y., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.020 · Cited by 737

The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo

Meerbrey, K. L., Hu, G., Kessler, J. D., Roarty, K. P., Li, M. Z., Fang, J. E., Herschkowitz, J. I., Burrows, A. E., Ciccia, A., Sun, T., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019736108 · Cited by 667

Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras

Wang, T., Yu, H., Hughes, N. W., Liu, B., Kendirli, A., Klein, K., Chen, W. W., Lander, E. S., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.01.013 · Cited by 632

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

Montagut, C. O., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M. J., Ulkus, L. E., Dias-Santagata, D. C., Stubbs, H., Lee, D. W., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 518

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding

Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507

Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?

Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., & Gray, N. S. (2014) · ACS Chemical Biology · doi:10.1021/cb500129t · Cited by 462

Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases

Marais, R., Light, Y., Paterson, H. F., Mason, C., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 455

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Hanna, N. H. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79219-4 · Cited by 386

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Peng, S.-B., Henry, J. R., Kaufman, M. D., Lu, W.-P., Smith, B. D., Vogeti, S., Rutkoski, T. J., Wise, S., Chun, L., Zhang, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.002 · Cited by 303

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

Blasco, R. B., Francoz, S., Santamaría, D., Cañamero, M., Dubus, P., Charron, J., Baccarini, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.002 · Cited by 302

Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas

Fransén, K. (2003) · Carcinogenesis · doi:10.1093/carcin/bgh049 · Cited by 274

Mutant BRAF Melanomas—Dependence and Resistance

Poulikakos, P. I., & Rosen, N. X. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.008 · Cited by 256

Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling

Haling, J. R., Sudhamsu, J., Yen, I., Sideris, S., Sandoval, W. N., Phung, W., Bravo, B. J., Giannetti, A. M., Peck, A., Masselot, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.007 · Cited by 242

Mutations of C-RAF Are Rare in Human Cancer because C-RAF Has a Low Basal Kinase Activity Compared with B-RAF

Emuss, V., Garnett, M. J., Mason, C., The Cancer Genome Project, & Marais, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1683 · Cited by 203

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

Clark, T. A., Chung, J. H., Kennedy, M., Hughes, J. D., Chennagiri, N., Lieber, D. S., Fendler, B., Young, L., Zhao, M., Coyne, M., et al. (2018) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.05.004 · Cited by 200

Ins and Outs of Kinase DFG Motifs

Treiber, D. K., & Shah, N. P. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.06.001 · Cited by 177

Somatic activating ARAF mutations in Langerhans cell histiocytosis

Nelson, D. S., Quispel, W. T., Badalian‐Very, G., van Halteren, A. G. S., van den Bos, C., Bovée, J. V. M. G., Tian, S. Y., Hummelen, P. V., Ducar, M. A., MacConaill, L. E., et al. (2014) · Blood · doi:10.1182/blood-2013-06-511139 · Cited by 173

Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape

Sekulić, A., Haluska, P., Miller, A. J., Lamo, J. G. D., Ejadi, S., Pulido, J. S., Salomão, D. R., Thorland, E. C., Vile, R. G., Swanson, D. C., et al. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.7.825 · Cited by 144

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J. M., Brennan, C. W., Shih, J.-Y., Riely, G. J., Viale, A. J., Wang, L., Chitale, D. A., Motoi, N., Szőke, J., Broderick, S., et al. (2007) · Molecular Cancer Therapeutics · Cited by 123

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Desai, J., Gan, H. K., Barrow, C., Jameson, M. B., Atkinson, V. G., Haydon, A. M., Millward, M., Begbie, S. D., Brown, M. P., Markman, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02654 · Cited by 117

A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas

Sun, Y., Alberta, J. A., Pilarz, C., Calligaris, D., Chadwick, E. J., Ramkissoon, S. H., Ramkissoon, L. A., Matía, V., Mazzola, E., Goumnerova, L. C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now261 · Cited by 107

Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization

Liau, N. P. D., Wendorff, T. J., Quinn, J. G., Steffek, M., Phung, W., Liu, P., Tang, J., Irudayanathan, F. J., Izadi, S., Shaw, A. S., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0365-0 · Cited by 96

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition

Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0768 · Cited by 94

LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

Monaco, K., Delach, S. M., Yuan, J., Mishina, Y. M., Fordjour, P., Labrot, E., McKay, D., Guo, R., Higgins, S., Wang, H. Q., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2563 · Cited by 91

ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers

Rebocho, A. P., & Marais, R. (2012) · Oncogene · doi:10.1038/onc.2012.330 · Cited by 83

BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF -Mutated Colorectal Cancers

Tang, Z., Yuan, X., Du, R., Cheung, S.-H., Zhang, G., Wei, J., Zhao, Y., Feng, Y., Peng, H., Zhang, Y., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0262 · Cited by 82

C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E

Karreth, F. A., DeNicola, G. M., Winter, S. P., & Tuveson, D. A. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.10.017 · Cited by 64

RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma

Dorard, C., Estrada, C., Barbotin, C., Larcher, M., Garancher, A., Leloup, J., Beermann, F., Baccarini, M., Pouponnot, C., Larue, L., et al. (2017) · Nature Communications · doi:10.1038/ncomms15262 · Cited by 60

Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.

Kim, T. W., Lee, J., Shin, S. J., Kim, J.-S., Kim, Y. J., Han, H. S., Lee, S. J., Lim, H., Hong, Y.-H., Noh, Y. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3000 · Cited by 49

Mutational analysis of the ARAF gene in human cancers

Lee, J. W., Soung, Y. H., Kim, S. Y., Park, W. S., Nam, S. W., Min, W. S., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2005) · Apmis · doi:10.1111/j.1600-0463.2005.apm1130108.x · Cited by 47

Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic

Ramurthy, S., Taft, B. R., Aversa, R. J., Barsanti, P. A., Burger, M. T., Lou, Y. C., Nishiguchi, G., Rico, A. C., Setti, L., Smith, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00161 · Cited by 43

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors

Yuan, X., Tang, Z., Du, R., Yao, Z., Cheung, S., Zhang, X., Wei, J., Zhao, Y., Du, Y., Liu, Y., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12698 · Cited by 40

CSIG-19. FHL2 INTERACTS WITH EGFRVIII TO PROMOTE GLIOBLASTOMA GROWTH

Sun, L., Lan, Q., & Li, M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox168.213 · Cited by 7

Signal pathways of melanoma and targeted therapy

Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 419

Small molecule inhibitors targeting the cancers

Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 212

E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers

Park, H., & Baek, K. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188736 · Cited by 184

The RASopathies: from pathogenetics to therapeutics

Hebron, K. E., Hernandez, E. R., & Yohe, M. E. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049107 · Cited by 177

Molecular Pathways and Mechanisms of BRAF in Cancer Therapy

Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2138 · Cited by 145

Abstract 36: ARAF mutations confer resistance to RAF dimer inhibitors in NRAS and BRAF mutant melanoma

Malek, S. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-36

ARAF Mutations Limit Response to RAF Dimer Inhibition

(2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2021-069 · Cited by 4

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454

Abstract A012: Emergence of MEK1 mutations in RAF or RAS-mutant solid tumors following treatment with a combination of selective type II RAF inhibitor belvarafenib and MEK inhibitor cobimetinib

Hilz, S., Chen, M., Nowicka, M., Chakravarthy, H., Moshref, M., Gerosa, L., Eng‐Wong, J., Chou, C. K., Noh, Y. S., Hong, Y.-H., et al. (2024) · Cancer Research · doi:10.1158/1538-7445.canevol23-a012

Abstract IA7: Novel mechanisms of resistance in BRAF-mutant melanoma

Poulikakos, P. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.mechres-ia7